Wegovy Approved for Adolescents: What Parents and Teens Need to Know

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your treatment plan.

The FDA Approval: Key Details

In December 2022, the FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in pediatric patients aged 12 years and older with obesity, defined as a BMI at or above the 95th percentile for age and sex. This was a landmark regulatory decision — the first time an injectable GLP-1 receptor agonist had been approved for weight management in an adolescent population, and one of the most significant expansions of the FDA's obesity treatment approval framework to younger patients in decades.

The approval applies specifically to the Wegovy formulation — semaglutide at the 2.4 mg weekly dose, the same formulation approved for adults. It does not extend to Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg), which is approved only for type 2 diabetes. Adolescents being prescribed semaglutide for weight management should specifically receive Wegovy, not an off-label dose of Ozempic, though the prescribing decision ultimately belongs to the treating clinician.

The FDA's approval was accompanied by the same boxed warning that applies to adult Wegovy: a caution about the risk of thyroid C-cell tumors seen in rodent studies, which is a reason for Wegovy to not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The relevance of the rodent findings to humans is uncertain — MTC has not been reported in clinical trial participants — but the precautionary warning has been extended to the adolescent population.

The approval came on the heels of major updates to the American Academy of Pediatrics (AAP)'s clinical practice guidelines on childhood obesity, published in January 2023. The AAP guidelines for the first time explicitly recommended pharmacotherapy and, where appropriate, surgical intervention as components of comprehensive obesity treatment in children and adolescents — a significant shift from prior guidance that had emphasized behavioral intervention alone. The Wegovy approval and the AAP guideline update together represent a fundamental realignment of how the medical community approaches obesity in young people.

The dosing schedule for adolescents is identical to that used in adults: beginning at 0.25 mg once weekly for four weeks, then escalating in 0.25 mg to 0.5 mg increments every four weeks as tolerated, with a target maintenance dose of 2.4 mg weekly. The titration process takes approximately 16 to 20 weeks in total, allowing the gastrointestinal system to adapt gradually and reducing the severity of nausea and other side effects during dose escalation.

Clinical Trial Results in Adolescents

The FDA's approval was based primarily on data from the STEP TEENS trial (Semaglutide Treatment Effect in People with Obesity: Teens), a Phase 3a randomized, double-blind, placebo-controlled trial that enrolled 201 adolescents aged 12 to 17 years with obesity (BMI at or above the 95th percentile for age and sex). Participants were randomized 2:1 to receive semaglutide 2.4 mg weekly or placebo, alongside behavioral intervention counseling. The primary endpoint was change in BMI from baseline to week 68.

The results were striking. Participants receiving semaglutide experienced an average reduction in BMI of 16.1 percent from baseline, while those on placebo experienced an average increase of 0.6 percent — a treatment difference of 16.7 percentage points. In terms of weight loss, the semaglutide group lost an average of 15.3 kg (33.7 pounds), while the placebo group gained an average of 2.4 kg (5.3 pounds). These are among the largest weight loss outcomes ever reported in a pharmacological trial in an adolescent population.

The proportion of adolescents achieving clinically meaningful weight reduction milestones was also high. Approximately 73 percent of those on semaglutide achieved at least 5 percent BMI reduction, 62 percent achieved at least 10 percent, and 45 percent achieved at least 20 percent — thresholds associated with meaningful improvements in metabolic health markers including blood pressure, blood glucose, triglycerides, and inflammatory markers. Importantly, the metabolic improvements paralleled the weight changes, with significant improvements across cardiovascular risk factors in the semaglutide group relative to placebo.

Secondary endpoints including quality of life, as measured by the Pediatric Quality of Life Inventory (PedsQL), also showed meaningful improvements in the semaglutide group. Physical functioning, emotional functioning, and overall health scores all improved more in the treatment group than in the placebo group. This is an important finding because it addresses a concern sometimes raised about pharmacological weight management in adolescents — that the focus on weight might harm psychological wellbeing. Within this trial, the opposite appeared to be true: effective weight loss was associated with improvements in self-reported quality of life across multiple domains.

The safety profile in STEP TEENS was broadly consistent with what has been observed in adult trials, with gastrointestinal adverse events — nausea, vomiting, diarrhea, and constipation — being the most common side effects. These occurred more frequently in the semaglutide group than in the placebo group, as expected, but were predominantly mild to moderate in severity and resolved or improved over time as dose titration continued. The rate of treatment discontinuation due to adverse events was low (approximately 4 percent in the semaglutide group), suggesting acceptable tolerability in this population.

Who Qualifies for Adolescent Wegovy?

The FDA approval specifies that Wegovy is indicated for adolescents aged 12 and older with obesity, defined as a BMI at or above the 95th percentile for age and sex. Note that this is a different BMI threshold than that used for adults — for adolescents, BMI is not interpreted using the same absolute cutoffs (30 for obesity, 40 for severe obesity) but rather as a percentile relative to peers of the same age and sex, using the CDC's reference growth charts.

In practice, a BMI at the 95th percentile corresponds to different absolute values at different ages. At age 12, the 95th percentile for boys is approximately 22.6 kg/m2 and for girls approximately 23.5 kg/m2 — values that would not qualify as overweight, let alone obese, for an adult. This reflects the fact that adolescents are still growing and developing, and absolute BMI values must be interpreted in the context of normal growth. Pediatric healthcare providers use age- and sex-specific growth charts to make this determination, and the calculation is routinely performed at well-child visits.

Beyond BMI, prescribers will also consider the overall clinical picture: the presence of weight-related comorbidities (pre-diabetes, hypertension, dyslipidemia, sleep apnea, fatty liver disease, joint problems), the history of prior behavioral intervention, family history of obesity and related metabolic conditions, and the teen's readiness and motivation to engage with treatment. Wegovy is not intended as a standalone treatment — it should be used as part of a comprehensive program that includes dietary counseling, physical activity guidance, and behavioral support.

Wegovy is contraindicated in adolescents (as in adults) with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is also contraindicated in patients with a known hypersensitivity to semaglutide or any component of the formulation. Adolescents with a history of pancreatitis, gallbladder disease, or significant renal impairment warrant careful evaluation before initiating treatment, as these are potential risks across the GLP-1 class.

Because adolescent obesity medicine is a specialized area, many pediatric endocrinologists, adolescent medicine specialists, and childhood obesity programs have developed specific protocols for evaluating and monitoring young patients on Wegovy. If your child's pediatrician is not familiar with prescribing GLP-1 medications in adolescents, asking for a referral to a specialist — pediatric endocrinologist or an adolescent weight management program — is entirely appropriate and likely to result in more comprehensive care.

Safety Considerations for Young Patients

The safety considerations for adolescents on Wegovy largely mirror those for adults, but with some additional nuances specific to the developing body. Adolescence is a period of significant physiological change — bones are growing, organ systems are maturing, nutritional requirements are elevated, and the hormonal environment is in flux. GLP-1 medications reduce food intake substantially, and ensuring that this reduced intake still provides adequate nutrition for healthy development is an important clinical and practical concern.

Protein intake is particularly important in growing adolescents because protein is essential for bone mineralization, muscle development, and tissue repair. When total caloric intake decreases substantially on GLP-1 therapy, there is a risk that protein intake falls below optimal levels unless active attention is paid to food choices. Dietitian involvement is strongly recommended for adolescents on Wegovy to help navigate this challenge — ensuring that the foods they choose when they do eat are nutritionally dense and protein-adequate.

Bone health is another area of attention in adolescent GLP-1 therapy. Adolescence is the critical period for building peak bone mass — the bone density accumulated during the teenage years largely determines bone strength for the rest of life. Calcium and vitamin D intake must be monitored and supplemented as needed. Physical activity, particularly weight-bearing exercise, is important for bone health and should be encouraged and supported as part of any comprehensive adolescent obesity treatment program.

Growth monitoring is an essential component of ongoing care for adolescents on Wegovy. Height should be tracked regularly to ensure that weight loss is not occurring at the expense of normal linear growth. To date, data from STEP TEENS did not identify significant growth impairment in trial participants, but this was a 68-week trial and longer-term surveillance data in real-world populations will be important. Clinicians should maintain a growth chart and assess growth velocity at each visit.

Gallbladder disease — gallstones and cholecystitis — is a known risk of rapid weight loss across all ages and has been reported as a side effect of GLP-1 therapy in clinical trials. Adolescents who experience significant upper abdominal pain, nausea, or pain radiating to the right shoulder during treatment should be evaluated promptly, as these may be symptoms of gallbladder disease. While gallstone risk in adolescents is generally lower than in adults, it is not negligible in the context of significant weight loss.

Insurance Coverage for Adolescents

Insurance coverage for Wegovy in adolescents has been inconsistent and in many cases more restrictive than coverage for adults. While the FDA approval provides the legal basis for coverage, commercial insurance plans and Medicaid programs set their own formulary policies and prior authorization criteria, which may differ significantly from the FDA's approved indication.

Many commercial insurance plans that cover Wegovy for adults have extended that coverage to adolescents, though often with stringent prior authorization requirements. These typically include documentation of obesity (BMI at or above the 95th percentile confirmed by a provider), evidence of failed behavioral intervention (dietary counseling, exercise program participation for a specified duration), and in some cases a psychological evaluation. Working with a prescriber familiar with the prior authorization process for adolescent obesity is important — the documentation requirements are specific and incomplete submissions are a common cause of denial.

Medicaid coverage for adolescent Wegovy varies significantly by state. Some state Medicaid programs cover GLP-1 medications for obesity in both adults and adolescents, while others restrict coverage to diabetes indications or exclude obesity medications entirely. Given that childhood obesity disproportionately affects lower-income families — who are more likely to be covered by Medicaid — the variability in Medicaid coverage is a significant equity issue. Advocacy organizations including the Obesity Medicine Association and the Obesity Action Coalition track Medicaid coverage policies by state and can be valuable resources for families navigating this landscape.

If insurance coverage is denied, the appeals process is an important tool. A significant proportion of initial prior authorization denials for GLP-1 medications are overturned on appeal when robust clinical documentation is provided. Your prescriber or the prescriber's office staff should be able to help with the appeals process, and many obesity medicine practices have dedicated staff to manage insurance navigation.

For families without adequate insurance coverage, Novo Nordisk's patient assistance program (NovoCare) provides Wegovy at no cost for qualifying families who meet income criteria. The application requires documentation of income and insurance status and can be submitted by the prescribing provider. While the process takes some time, it is a meaningful resource for families who cannot otherwise afford treatment. Your child's prescriber or a hospital social worker can help initiate the application.

Having the Conversation with Your Teen

For many families, the decision to initiate pharmacological treatment for a teenager's weight is emotionally complex. Weight is a sensitive topic for adolescents — a developmental period when body image is particularly salient, peer comparison is intense, and self-esteem is fragile. The conversation around Wegovy needs to be handled with care, centering the teen's wellbeing, autonomy, and emotional experience rather than emphasizing appearance or social acceptance.

Before initiating any conversation with your teenager about Wegovy, it is worth reflecting on your own assumptions and feelings about weight and body size. Research on weight stigma is clear: adolescents who experience weight-based teasing or criticism — including from parents — are more likely to develop disordered eating, depression, and anxiety, and are paradoxically more likely to gain weight over time. The goal of any conversation should be to support your teenager's health and wellbeing — not to pressure them toward a particular body size.

Frame the conversation around health — specifically, around how their weight may be affecting how they feel physically and functionally. Ask open-ended questions: "How are you feeling day to day?" "Are there activities you wish you could do more easily?" "Does your weight ever get in the way of things you want to do?" These questions invite the teenager to share their own perspective rather than receiving a lecture about their weight. Teenagers who feel heard and respected in this conversation are far more likely to engage meaningfully with treatment.

Involve your teenager in the decision-making process as much as possible. Adolescents who feel that treatment is being done to them rather than with them are less likely to adhere and more likely to experience negative psychological impacts. This means explaining what Wegovy is, how it works, what the likely side effects are, and what the expected outcomes might be — in terms the teenager can understand and relate to. It also means making clear that the decision is theirs to participate in, not a mandate imposed by parents or providers.

Mental health support is strongly recommended as a component of adolescent GLP-1 therapy. A therapist who specializes in adolescent health, body image, and eating-related issues can provide an important emotional scaffold for the teenager as they navigate treatment. GLP-1 medications change the relationship with food in profound ways — reduced appetite, altered food preferences, and decreased food-related reward can all create psychological adjustments that benefit from professional guidance. There is also evidence that rapid physical changes during adolescence can affect identity and peer relationships in complex ways that benefit from therapeutic support.

Finally, be prepared for the long-term nature of this treatment. Weight regain after discontinuation of semaglutide is well documented in adults and is expected in adolescents as well. Framing Wegovy as a tool to help your teenager build healthy habits — rather than as a solution that will work independently of other efforts — sets realistic expectations and supports the kind of comprehensive behavioral change that makes long-term outcomes most favorable. This is a marathon, not a sprint, and the family environment and support around the teenager will matter enormously for how well the treatment ultimately serves them.